Antibody Drug Conjugates (ADCs) have revolutionized targeted cancer therapy by combining the specificity of antibodies with the potency of cytotoxic drugs. At the heart of these innovative therapies lie ADC linkers, critical components that connect the drug to the antibody, ensuring precise delivery to cancer cells while minimizing damage to healthy tissue.
ADC linkers, also known as antibody drug conjugate linkers, are specialized molecules that securely attach the cytotoxic drug (also called the payload) to the antibody. These linkers play a vital role in maintaining the stability of the conjugate while circulating in the bloodstream and releasing the drug only at the target site.
One of the most common types of linkers used in ADCs is the protease cleavable linker. These linkers are designed to be stable in the bloodstream but cleaved by specific enzymes (proteases) that are abundant in cancer cells. This selective cleavage ensures that the cytotoxic drug is released precisely where it is needed, enhancing the efficacy and safety of the therapy.
As leading ADC linkers manufacturers in India, Shilpa Pharma is committed to delivering high-quality, reliable, and innovative drug linkers for the pharmaceutical and biotech industries. Our advanced manufacturing processes and strict quality control ensure that our ADC linkers meet the highest standards for research and clinical use.
By partnering with Shilpa, you gain access to cutting-edge linker technologies, including a range of protease cleavable linkers and other custom solutions designed to meet your specific requirements.